Semaglutide Reduces Mace Consistently Across Baseline Triglyceride Levels in Patients With Type 2 Diabetes: A Post Hoc Analysis of the Sustain 6 and Pioneer 6 Trials

被引：0
|
作者：
Verma, Subodh
Leiter, Lawrence A.
Michelsen, Marie M.
Orsted, David
Rasmussen, Soren
Bhatt, Deepak L.
机构：
来源：
CIRCULATION | 2020年 / 142卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A13814
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials
    Verma, Subodh
    David, Jens-Peter
    Leiter, Lawrence A.
    Michelsen, Marie Mide
    Rasmussen, Soren
    Bhatt, Deepak L.
    DIABETES OBESITY & METABOLISM, 2023, 25 (08): : 2388 - 2392
  • [2] Effect of semaglutide on MACE by baseline kidney function in participants with type 2 diabetes and high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc analysis
    Rossing, P.
    Bain, S.
    Bosch-Traberg, H.
    Frenkel, O.
    Heerspink, H. L.
    Rasmussen, S.
    Mellbin, L.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S24 - S25
  • [3] Effects of liraglutide and semaglutide on stroke subtypes in patients with type 2 diabetes: a post hoc analysis of the LEADER, SUSTAIN 6 and PIONEER 6 trials
    Strain, W. D.
    Holst, A. G.
    Rasmussen, S.
    Saevereid, H. A.
    James, M. A.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S130 - S131
  • [4] Effects of liraglutide and semaglutide on stroke subtypes in patients with type 2 diabetes: a post hoc analysis of the LEADER, SUSTAIN 6 and PIONEER 6 trials
    Strain, W. D.
    Holst, A. G.
    Rasmussen, S.
    Saevereid, H. A.
    James, M. A.
    EUROPEAN HEART JOURNAL, 2020, 41 : 2424 - 2424
  • [5] Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6
    Strain, W. David
    Frenkel, Ofir
    James, Martin A.
    Leiter, Lawrence A.
    Rasmussen, Soren
    Rothwell, Peter M.
    Ripa, Maria Sejersten
    Truelsen, Thomas C.
    Husain, Mansoor
    STROKE, 2022, 53 (09) : 2749 - 2757
  • [6] Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6
    Bain, Stephen C.
    Belmar, Nicolas
    Hoff, Soren T.
    Husain, Mansoor
    Rasmussen, Soren
    Vilsboll, Tina
    Petrie, Mark C.
    DIABETES THERAPY, 2025, 16 (01) : 15 - 28
  • [7] Semaglutide reduces hsCRP levels across different treatment settings: post hoc analyses of SUSTAIN and PIONEER trials
    Mosenzon, O.
    Capehorn, M.
    De Remigis, A.
    Rasmussen, S.
    Weimers, P.
    Rosenstock, J.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 95 - 96
  • [8] Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
    Husain, Mansoor
    Consoli, Agostino
    De Remigis, Alessandra
    Meyer, Anna Sina Pettersson
    Rasmussen, Soren
    Bain, Stephen
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [9] Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
    Mansoor Husain
    Agostino Consoli
    Alessandra De Remigis
    Anna Sina Pettersson Meyer
    Søren Rasmussen
    Stephen Bain
    Cardiovascular Diabetology, 21
  • [10] Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme
    Bain, S.
    Rea, R.
    Warren, M.
    Holst, A. G.
    Vrazic, H.
    Madsbad, S.
    EUROPEAN HEART JOURNAL, 2018, 39 : 598 - 598
12345